Study of Low Level Laser Light Therapy to Improve Blood Circulation in People With Chronic Heel Pain
CompletedNot applicableNCT01882725
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine whether low level laser light therapy is effective in increasing local blood circulation in people with chronic heel pain arising from plantar fasciitis.
Study details
- Official title
- An Evaluation of the Effect of the Erchonia HP Scanner (HPS) Laser on Increasing Blood Circulation in Individuals With Chronic Heel Pain
- Conditions
- Defective
- Circulation
- Interventions
- Device: Erchonia HP Scanner (HPS)
- Sponsor
- Erchonia Corporation
- Start date
- 2013-06
- Primary completion
- 2013-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Unilateral Mechanical Plantar Heel Pain: insertional heel pain of the plantar fascia - plantar fasciitis - in one heel * Chronic heel pain defined as at least 3 months of ongoing heel pain with no evidence of acute trauma to the heel * A self-rating on the 0-100 Visual Analog Scale of at least 50 for heel pain experienced upon taking the first few steps of the study qualification evaluation day (recorded retrospectively), to be confirmed by the two-day average VAS attained during the Baseline Washout phase. * Heel pain has been previously unresponsive to prescription non-steroidal anti-inflammatory drugs (NSAIDs) taken over a minimum period of 2 weeks; and any two or more of the following conservative treatments: rest, taping, stretching, orthotics, shoe modifications, night splinting, casting, physical therapy, or local corticosteroid injections. * Subject is willing and able to refrain from consuming over-the-counter and/or prescription medications for the indication of the relief of pain throughout the study. * Subject is willing and able to refrain from partaking in other non-study treatments or therapies for the relief of heel pain throughout the study. Exclusion Criteria: * Subject does not have any one or more of the following etiologies of chronic heel pain: Mechanical Posterior Heel Pain; Neurologic Heel Pain; Arthritic Heel Pain; and Traumatic Heel Pain * Evidence of acute trauma to the heel * Loss of plantar foot sensation * Foot deformity * Previous surgery to the heel * Foot trauma within the previous three months * Skin ulceration - infection or wound - on the heel and surrounding treatment area * Sciatica * Benign and malignant tumors * Acute infection of soft tissue/bone, e.g. osteomyelitis * Presence of diabetic neuropathic pain * Diabetes Type I * Presence of sensory neuropathy * Previous diagnosis of neuropathy affecting lower extremities * Peripheral vascular disease or autoimmune disease * Fibromyalgia * Chronic fatigue syndrome * Chronic pain disorders * Metabolic disorders: Osteomalacia, Paget's disease, Sickle cell disease * Blood coagulation disorders * Significant heart conditions including Congestive Heart Failure (CHF) and implantable heart devices * Non-ambulatory status * Unable or unwilling to consume the study rescue medication of Tylenol * Photosensitivity disorder * Pregnant or lactating * Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years * …
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01882725